RS62969B1 - Lečenje fragilnog x sindroma i autizma kanabidiolom - Google Patents

Lečenje fragilnog x sindroma i autizma kanabidiolom

Info

Publication number: RS62969B1
Authority: RS; Serbia
Prior art keywords: cannabidiol; autism; fragile; syndrome; treatment
Prior art date: 2017-09-28

Application number

RS20220123A

Other languages

English (en)

Inventor

Marcel Bonn-Miller

Nancy Tich

Donna Gutterman

John Messenheimer

Terri Sebree

Original Assignee

Zynerba Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-09-28

Filing date

2018-09-27

Publication date

2022-03-31

2018-09-27 Application filed by Zynerba Pharmaceuticals Inc filed Critical Zynerba Pharmaceuticals Inc

2022-03-31 Publication of RS62969B1 publication Critical patent/RS62969B1/sr

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Natural Medicines & Medicinal Plants (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Dermatology (AREA)
Biotechnology (AREA)
Alternative & Traditional Medicine (AREA)
Botany (AREA)
Medical Informatics (AREA)
Microbiology (AREA)
Mycology (AREA)
Psychiatry (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

RS20220123A 2017-09-28 2018-09-27 Lečenje fragilnog x sindroma i autizma kanabidiolom RS62969B1 (sr)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US201762564834P	2017-09-28	2017-09-28
US201862632532P	2018-02-20	2018-02-20
PCT/IB2018/057519 WO2019064234A1 (en)	2017-09-28	2018-09-27	TREATMENT OF FRAGILE X SYNDROME WITH CANNABIDIOL
EP18788905.0A EP3687513B1 (en)	2017-09-28	2018-09-27	Treatment of fragile x syndrome and autism with cannabidiol

Publications (1)

Publication Number	Publication Date
RS62969B1 true RS62969B1 (sr)	2022-03-31

Family

ID=63878731

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
RS20220123A RS62969B1 (sr)	2017-09-28	2018-09-27	Lečenje fragilnog x sindroma i autizma kanabidiolom

Country Status (22)

Country	Link
US (11)	US10213390B1 (sr)
EP (3)	EP3967301B1 (sr)
JP (3)	JP7210564B2 (sr)
KR (1)	KR20220045070A (sr)
AU (2)	AU2018343256B2 (sr)
BR (1)	BR112020005918A2 (sr)
CA (1)	CA3077330A1 (sr)
CY (1)	CY1125071T1 (sr)
DK (1)	DK3687513T3 (sr)
ES (2)	ES2907325T3 (sr)
HR (1)	HRP20220277T1 (sr)
HU (1)	HUE058102T2 (sr)
IL (1)	IL273495A (sr)
JO (1)	JOP20200082A1 (sr)
LT (1)	LT3687513T (sr)
MX (2)	MX2020003606A (sr)
PL (1)	PL3687513T3 (sr)
PT (1)	PT3687513T (sr)
RS (1)	RS62969B1 (sr)
SI (1)	SI3687513T1 (sr)
SM (1)	SMT202200093T1 (sr)
WO (1)	WO2019064234A1 (sr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SMT202200093T1 (it) *	2017-09-28	2022-05-12	Zynerba Pharmaceuticals Inc	Trattamento della sindrome dell’x fragile e dell'autismo con cannabidiolo
AU2019396750A1 (en)	2018-12-14	2021-07-08	Harmony Biosciences Management, Inc.	Treatment of 22q11.2 deletion syndrome with cannabidiol
GB201912760D0 (en) *	2019-09-05	2019-10-23	Healx Ltd	Treatment
US12016829B2 (en)	2019-10-11	2024-06-25	Pike Therapeutics Inc.	Pharmaceutical composition and method for treating seizure disorders
EP4041209A4 (en)	2019-10-11	2024-01-24	Pike Therapeutics, Inc.	TRANSDERMAL COMPOSITIONS CONTAINING CANNABIDIOL (CBD) FOR USE IN THE TREATMENT OF SEIZURE DISORDERS
US12121617B2 (en)	2019-10-14	2024-10-22	Pike Therapeutics Inc.	Transdermal delivery of cannabidiol
WO2021074790A1 (en)	2019-10-14	2021-04-22	Pike Therapeutics, Inc., 1219014 B.C. Ltd.	Transdermal delivery of cannabidiol
GB2589306A (en) *	2019-10-25	2021-06-02	Gw Res Ltd	Use of cannabidiol preparations in the treatment of fragile X syndrome
JP7412583B2 (ja)	2020-02-07	2024-01-12	ニューロヴェンティカンパニーリミテッド	リルメニジン化合物を有効成分として含む脆弱ｘ症候群または関連発達障害を治療するための組成物
BR112022023928A2 (pt) *	2020-05-26	2022-12-27	Zynerba Pharmaceuticals Inc	Uso de canabidiol para o tratamento do transtorno do espectro autista
AU2021301406A1 (en) *	2020-06-29	2023-02-02	Harmony Biosciences Management, Inc.	Treatment of fragile x syndrome with cannabidiol
JP2023552390A (ja) *	2020-12-03	2023-12-15	ジナーバ・ファーマシューティカルズ・インコーポレイテッド	難治性発作の治療
CA3235677A1 (en) *	2021-10-22	2023-04-27	Joseph Palumbo	Treatment of irritability in subjects with autism spectrum disorders with moderate to severe anxiety and/or social avoidance

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8449908B2 (en)	2000-12-22	2013-05-28	Alltranz, Llc	Transdermal delivery of cannabidiol
FI20020333A0 (fi)	2002-02-20	2002-02-20	Tomi Jaervinen	Metyloidun syklodekstriinin uudet kompleksit
TWI366460B (en)	2005-06-16	2012-06-21	Euro Celtique Sa	Cannabinoid active pharmaceutical ingredient for improved dosage forms
WO2008060375A2 (en) *	2006-10-06	2008-05-22	The Regents Of The University Of Californina	Upregulating bdnf levels to mitigate mental retardation
EP2176208B1 (en)	2007-07-30	2015-01-21	Zynerba Pharmaceuticals, Inc.	Prodrugs of cannabidiol, compositions comprising prodrugs of cannabidiol and methods of using the same
MX2011011514A (es)	2009-04-28	2011-11-18	Alltranz Inc	Formulaciones de canabidiol y metodos para utilizarlas.
US20110052694A1 (en)	2009-08-31	2011-03-03	Alltranz Inc.	Use of cannabidiol prodrugs in topical and transdermal administration with microneedles
US9447019B2 (en)	2013-01-08	2016-09-20	Universidade De Sao Paulo-Usp	Fluorinated CBD compounds, compositions and uses thereof
CA2929321C (en)	2013-10-29	2022-04-05	Echo Pharmaceuticals B.V.	Compressed tablet containing cannabidiol, method for its manufacture and use of such tablet in oral treatment of psychosis or anxiety disorders
US20160022627A2 (en)	2014-04-18	2016-01-28	Mary's Medicinals LLC	Transdermal cannabinoid patch
US20160271252A1 (en)	2014-05-29	2016-09-22	Insys Development Company, Inc.	Stable cannabinoid formulations
KR20170008311A (ko)	2014-05-29	2017-01-23	인시스 파마, 인코포레이티드	안정한 카나비노이드 제형
US20170224634A1 (en)	2014-05-29	2017-08-10	Insys Development Company, Inc.	Stable cannabinoid formulations
US11331279B2 (en)	2014-05-29	2022-05-17	Radius Pharmaceuticals, Inc.	Stable cannabinoid formulations
CA2953684C (en)	2014-06-27	2023-01-03	Kenton L. Crowley	Buccal and sublingual cannabinoid formulations and method of making the same
US20160000843A1 (en)	2014-07-01	2016-01-07	MJAR Holdings, LLC	High cannabidiol cannabis strains
GB2531278A (en)	2014-10-14	2016-04-20	Gw Pharma Ltd	Use of cannabidiol in the treatment of intractable epilepsy
NZ731248A (en)	2014-10-21	2024-04-26	United Cannabis Corp	Cannabis extracts and methods of preparing and using same
US9375417B2 (en)	2014-12-04	2016-06-28	Mary's Medicinals LLC	Transdermal cannabinoid formulations
WO2016109624A1 (en)	2014-12-30	2016-07-07	University Of Houston System	Pharmaceutical compositions
US20160338974A1 (en)	2015-03-02	2016-11-24	Afgin Pharma, Llc	Topical regional neuro affective therapy with cannabinoid combination products
MX2017011280A (es)	2015-03-02	2018-06-27	Afgin Pharma Llc	Terapia neuro-afectiva regional topica con cannabinoides.
WO2017068349A1 (en)	2015-10-23	2017-04-27	E-Therapeutics Plc	Cannabinoid for use in immunotherapy
WO2017151980A1 (en)	2016-03-03	2017-09-08	Segreti Louis M	Cannabis-based bioactive formulations and methods for use thereof
EP3423047A4 (en)	2016-03-04	2020-01-01	Sharon Anavi-Goffer	Compositions of cb2 receptor selective agonists for treatment of mental disorders
WO2017158539A1 (en)	2016-03-16	2017-09-21	Buzzelet Development And Technologies Ltd	Terpene-enriched cannabinoid composition
GB2549277B (en)	2016-04-11	2021-02-17	Gw Res Ltd	Cannabidiolic Acid for use in the Treatment of Autism Spectrum Disorder
GB2549278B (en)	2016-04-11	2021-02-17	Gw Res Ltd	Use of cannabidivarin in the treatment of autism spectrum disorder
IL262419B2 (en)	2016-04-19	2024-08-01	Canna B Cure Ltd	A therapeutic composition containing enzyme-rich cannabis
KR102433459B1 (ko)	2016-06-02	2022-08-17	아세러스 랩스 인코포레이티드	칸나비노이드의 반고체 및 점성 액체 비강 제형
GB2551987A (en)	2016-07-01	2018-01-10	Gw Res Ltd	Oral cannabinoid formulations
IL246790A0 (en)	2016-07-14	2016-09-29	Friedman Doron	Self-dissolving compounds of cannabinoids
GB2557921A (en)	2016-12-16	2018-07-04	Gw Res Ltd	Use of cannabinoids in the treatment of angelman syndrome
CN107126411A (zh)	2017-03-22	2017-09-05	哈尔滨惠美佳生物科技有限公司	具有缓解神经性头痛作用的大麻二酚凝胶及其制备方法
WO2019034985A1 (en)	2017-08-14	2019-02-21	Zynerba Pharmaceuticals, Inc.	METHODS OF TREATING ARTHROSIS USING CANNABIDIOL TRANSDERMAL GEL
AU2018101357B4 (en)	2017-09-15	2022-03-17	Zelira Therapeutics Operations Pty Ltd	Composition and method for treating autism
SMT202200093T1 (it)	2017-09-28	2022-05-12	Zynerba Pharmaceuticals Inc	Trattamento della sindrome dell’x fragile e dell'autismo con cannabidiolo
US20230059709A1 (en)	2017-09-28	2023-02-23	Zynerba Pharmaceuticals, Inc.	Treatment of fragile x syndrome with cannabidiol
WO2019089583A1 (en)	2017-10-30	2019-05-09	Endocanna Health, Inc.	Cannabinoid formulations
US20210196669A1 (en)	2018-05-24	2021-07-01	To Pharmaceuticals Llc	Cannabis-based compositions for the treatment of autistic spectrum disorders
US20230000792A1 (en)	2018-12-14	2023-01-05	Zynerba Pharmaceuticals, Inc.	Treatment of 22q11.2 deletion syndrome with cannabidiol
US20230000793A1 (en)	2018-12-14	2023-01-05	Zynerba Pharmaceuticals, Inc.	Treatment of 22q11.2 deletion syndrome with cannabidiol
AU2019396750A1 (en)	2018-12-14	2021-07-08	Harmony Biosciences Management, Inc.	Treatment of 22q11.2 deletion syndrome with cannabidiol
BR112022023928A2 (pt)	2020-05-26	2022-12-27	Zynerba Pharmaceuticals Inc	Uso de canabidiol para o tratamento do transtorno do espectro autista
AU2021301406A1 (en)	2020-06-29	2023-02-02	Harmony Biosciences Management, Inc.	Treatment of fragile x syndrome with cannabidiol
GB2597322A (en)	2020-07-20	2022-01-26	Gw Res Ltd	Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
CA3235677A1 (en)	2021-10-22	2023-04-27	Joseph Palumbo	Treatment of irritability in subjects with autism spectrum disorders with moderate to severe anxiety and/or social avoidance

2018
- 2018-09-27 SM SM20220093T patent/SMT202200093T1/it unknown
- 2018-09-27 BR BR112020005918-8A patent/BR112020005918A2/pt unknown
- 2018-09-27 WO PCT/IB2018/057519 patent/WO2019064234A1/en active Application Filing
- 2018-09-27 ES ES18788905T patent/ES2907325T3/es active Active
- 2018-09-27 EP EP21206188.1A patent/EP3967301B1/en active Active
- 2018-09-27 ES ES21206188T patent/ES2992838T3/es active Active
- 2018-09-27 EP EP24174294.9A patent/EP4414030A3/en active Pending
- 2018-09-27 DK DK18788905.0T patent/DK3687513T3/da active
- 2018-09-27 HR HRP20220277TT patent/HRP20220277T1/hr unknown
- 2018-09-27 PT PT187889050T patent/PT3687513T/pt unknown
- 2018-09-27 US US16/144,632 patent/US10213390B1/en active Active
- 2018-09-27 LT LTEPPCT/IB2018/057519T patent/LT3687513T/lt unknown
- 2018-09-27 RS RS20220123A patent/RS62969B1/sr unknown
- 2018-09-27 KR KR1020227010520A patent/KR20220045070A/ko active Pending
- 2018-09-27 CA CA3077330A patent/CA3077330A1/en active Pending
- 2018-09-27 EP EP18788905.0A patent/EP3687513B1/en active Active
- 2018-09-27 SI SI201830564T patent/SI3687513T1/sl unknown
- 2018-09-27 HU HUE18788905A patent/HUE058102T2/hu unknown
- 2018-09-27 JO JOP/2020/0082A patent/JOP20200082A1/ar unknown
- 2018-09-27 PL PL18788905T patent/PL3687513T3/pl unknown
- 2018-09-27 AU AU2018343256A patent/AU2018343256B2/en active Active
- 2018-09-27 JP JP2020517930A patent/JP7210564B2/ja active Active
- 2018-09-27 MX MX2020003606A patent/MX2020003606A/es unknown
- 2018-12-14 US US16/220,249 patent/US10314792B2/en active Active
2019
- 2019-01-16 US US16/249,732 patent/US10471022B2/en active Active
- 2019-05-14 US US16/411,248 patent/US10568848B2/en active Active
- 2019-10-07 US US16/594,317 patent/US10758497B2/en active Active
2020
- 2020-01-08 US US16/737,326 patent/US20200214995A1/en not_active Abandoned
- 2020-03-22 IL IL273495A patent/IL273495A/en unknown
- 2020-07-13 MX MX2022012424A patent/MX2022012424A/es unknown
- 2020-08-06 US US16/986,622 patent/US11458110B2/en active Active
2021
- 2021-09-02 US US17/465,141 patent/US20220096396A1/en not_active Abandoned
2022
- 2022-02-03 JP JP2022015432A patent/JP2022064988A/ja active Pending
- 2022-02-22 CY CY20221100148T patent/CY1125071T1/el unknown
- 2022-08-24 US US17/895,008 patent/US11779549B2/en active Active
2023
- 2023-01-10 JP JP2023001500A patent/JP2023040166A/ja active Pending
- 2023-03-21 US US18/124,460 patent/US12213951B2/en active Active
- 2023-08-30 US US18/458,727 patent/US12226373B2/en active Active
2024
- 2024-09-25 AU AU2024220039A patent/AU2024220039A1/en active Pending

Also Published As

Publication number	Publication date
US20200030255A1 (en)	2020-01-30
MX2020003606A (es)	2020-10-28
US20190117588A1 (en)	2019-04-25
US10471022B2 (en)	2019-11-12
CA3077330A1 (en)	2019-04-04
US10314792B2 (en)	2019-06-11
EP3967301A1 (en)	2022-03-16
EP4414030A3 (en)	2024-11-20
ES2907325T3 (es)	2022-04-22
KR20200058513A (ko)	2020-05-27
US11458110B2 (en)	2022-10-04
DK3687513T3 (da)	2022-03-07
EP3967301B1 (en)	2024-06-19
SI3687513T1 (sl)	2022-04-29
SMT202200093T1 (it)	2022-05-12
US20230414533A1 (en)	2023-12-28
PT3687513T (pt)	2022-03-01
US10568848B2 (en)	2020-02-25
ES2992838T3 (en)	2024-12-18
HUE058102T2 (hu)	2022-07-28
US20190167605A1 (en)	2019-06-06
CY1125071T1 (el)	2023-06-09
US10758497B2 (en)	2020-09-01
JOP20200082A1 (ar)	2020-04-30
AU2018343256B2 (en)	2024-09-19
EP3687513A1 (en)	2020-08-05
IL273495A (en)	2020-05-31
WO2019064234A1 (en)	2019-04-04
US10213390B1 (en)	2019-02-26
JP2020535190A (ja)	2020-12-03
BR112020005918A2 (pt)	2020-10-06
MX2022012424A (es)	2022-11-30
JP2023040166A (ja)	2023-03-22
KR20220045070A (ko)	2022-04-12
US20230000790A1 (en)	2023-01-05
US12213951B2 (en)	2025-02-04
JP2022064988A (ja)	2022-04-26
US20200360299A1 (en)	2020-11-19
US12226373B2 (en)	2025-02-18
US20230364028A1 (en)	2023-11-16
PL3687513T3 (pl)	2022-04-19
US11779549B2 (en)	2023-10-10
HRP20220277T1 (hr)	2022-05-13
US20200214995A1 (en)	2020-07-09
EP3687513B1 (en)	2021-12-15
AU2024220039A1 (en)	2024-10-17
JP7210564B2 (ja)	2023-01-23
EP4414030A2 (en)	2024-08-14
LT3687513T (lt)	2022-03-10
AU2018343256A1 (en)	2020-04-02
US20190262280A1 (en)	2019-08-29
US20220096396A1 (en)	2022-03-31

Publication	Publication Date	Title
LT3687513T (lt)	2022-03-10	Trapiosios x chromosomos sindromo ir autizmo gydymas kanabidioliu
GB2548873B (en)	2020-12-02	Use of Cannabidiol in the Treatment of SturgeWeber Syndrome
IL259222A (en)	2018-07-31	Antisense oligomers for the treatment of autosomal dominant 5-mental retardation and Derva syndrome
GB201621480D0 (en)	2017-02-01	Use of cannabinoids in the treatment of angelman syndrome
ZA201800499B (en)	2018-12-19	Methods of treating lennox¿gastaut syndrome using fenfluramine
ZA201908447B (en)	2022-08-31	Bacitracin and/or daptomycin combined with cannabidiol for treatment of bacterial infections
IL268125A (en)	2019-09-26	Pridopidine for the treatment of fragile x syndrome
HK1251616A1 (zh)	2019-02-01	用於預防和/或治療感染性疾病以及用於治療腫瘤疾病的減毒流感病毒載體
IL244343A0 (en)	2016-04-21	Methods for the treatment of fragile x syndrome and related disorders
PL3727251T3 (pl)	2023-04-11	Wyrób chłonny i sposób jego wytwarzania
HUE046924T2 (hu)	2020-03-30	Módszerek és készítmények Barth szindróma megelõzésében vagy kezelésében történõ alkalmazásra
HK1256301A1 (zh)	2019-09-20	提高阿托伐他汀和清除感染的新的 13 系列消退素的說明
PL3727263T3 (pl)	2023-08-14	Wyrób chłonny i sposób jego wytwarzania
AU2017267955B2 (en)	2020-08-13	Reduced oxygen carriers and their use for the treatment of carboxyhemoglobinemia
ZA202002669B (en)	2021-05-26	Prevention and treatment of graft-versus-host-disease with defensins
HUE045242T2 (hu)	2019-12-30	Vírusfertõzések megelõzésére és terápiájára szánt ágens
GB2544874B (en)	2020-11-18	Medico-surgical tube assemblies and dressings
EP3316841A4 (en)	2019-02-13	ABSORBENT ARTICLE WITH OXYGEN FREEZING AND METHOD OF MANUFACTURING
EP2974726A4 (en)	2017-01-04	Agent for the prophylaxis and/or treatment of neoplastic diseases
SG11202004079PA (en)	2020-05-28	Treatment of post-traumatic syndrome disorder
GB201712162D0 (en)	2017-09-13	Absorbent article and method of manufacture
ZA201803649B (en)	2019-11-27	Attenuated influenza vectors for the prevention and/or treatment of infectious diseases and for the treatment of oncological diseases
EP3512600A4 (en)	2020-05-27	DRUG COMBINATIONS AND TREATMENT OF RESTLESS LEG SYNDROME
PL3280430T3 (pl)	2020-12-14	Peptyd QBP1 do stosowania w zapobieganiu lub leczeniu zespołu stresu pourazowego, ostrego zaburzenia stresowego oraz ogólnego zespołu adaptacyjnego
GB201519483D0 (en)	2015-12-16	Prevention and treatment of microbial infections